Publication

Article

Pharmacy Times

November 2013 Cough & Cold
Volume79
Issue 11

Diagnosis Terminology Affects Treatment Decisions

Women diagnosed with ductal carcinoma in situ, a noninvasive breast malignancy, may be more likely to choose surgery over noninvasive options when the condition is described using the word "cancer."

According to a recent study published online on August 26, 2013, in JAMA Internal Medicine, women diagnosed with ductal carcinoma in situ (DCIS), a noninvasive breast malignancy, may be more likely to choose surgery over noninvasive options when the condition is described using the word “cancer.”

Recognizing that many women are unable to distinguish between invasive and noninvasive cancers, especially with inconsistent terminology, the researchers investigated whether women’s treatment decisions would be affected by the words used to describe the diagnosis. The study enrolled 394 healthy women and presented them with 3 terms to describe a DCIS diagnosis: noninvasive breast cancer, breast lesion, and abnormal cells. Each term was accompanied by an identical table of risks and 3 treatment options, including surgery, medication, and active surveillance. Women viewed each term separately and were asked to make a treatment decision for each.

The results indicated that women changed their treatment decision when different terms were used to describe DCIS. When the condition was described as “noninvasive breast cancer,” 47% of women said they would want surgery. However, when DCIS was described as a “breast lesion,” 34% wanted surgery, and 31% selected surgery when “abnormal cells” was used.

The authors suggest that many women want nonsurgical treatment when they better understand the risks, but the word “cancer” may scare patients and prevent them from choosing less aggressive treatment.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com